Autres langues Pulse Biosciences, Inc.

Actions

PLSE

US74587B1017

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
7,25 ^USD	+0,83 %		+5,84 %	-40,77 %

01/04	Mise à jour sectorielle : Les actions du secteur de la santé chutent en fin d'après-midi	MT
01/04	Les actions de Pulse Biosciences chutent après les résultats du quatrième trimestre et les projets d'émission de droits	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	24/04
Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28/03
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14/03
Sector Update: Health Care Stocks Ease Late Afternoon	08/03
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	08/03
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pulse Biosciences, Inc.

Actions

PLSE

US74587B1017

Autres langues

Filtres